ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Urinary diversion and reconstruction following cystectomy

Urinary diversion and reconstruction following cystectomy
Literature review current through: Jan 2024.
This topic last updated: Jan 08, 2024.

INTRODUCTION — Removal of the bladder (cystectomy) is required to treat certain malignant (eg, bladder, colorectal cancer) or nonmalignant conditions (eg, congenital anomaly, trauma, neurologic disorders) [1-3]. After cystectomy, urine needs to be redirected with a urinary diversion and reconstruction procedure.

Ureterosigmoidostomy, which relied upon the anal sphincter for continence, was the first widely used surgical technique of urinary diversion. Its usefulness, however, was limited by deterioration of renal function over time, metabolic complications, and the development of secondary sigmoid colon cancers. (See 'Complications' below.)

Newer urinary diversion techniques, including continent cutaneous diversions and internal reservoirs connected to the native urethra, have improved quality of life and patient acceptance by permitting volitional voiding. Earlier patient acceptance of radical cystectomy in the natural history of bladder cancer may ultimately improve the outcome of bladder cancer treatment [4].

This topic discusses the three reconstructive options most widely used after cystectomy, ileal conduit, continent cutaneous diversion, and orthotopic neobladder. The management of bladder cancer is discussed separately, as are the techniques of radical cystectomy:

(See "Overview of the initial approach and management of urothelial bladder cancer".)

(See "Radical cystectomy".)

RECONSTRUCTIVE OPTIONS

Conduits and reservoirs — In urinary diversion, a conduit or a continent reservoir is required to replace the bladder and provide an internal reservoir or facilitate transit of urine to an external appliance. The ideal characteristics of a urinary reservoir are listed in the following table (table 1).

Urinary conduits and reservoirs are typically constructed from an isolated segment of bowel. In theory, any segment of bowel can be used to form a urinary diversion. However, there are metabolic consequences to using each bowel segment, determined by its absorptive function [5-21]. While most metabolic abnormalities are clinically subtle, they may assume significance in patients with renal insufficiency and in adolescents and young adults who will be subjected to the metabolic abnormalities for a prolonged period. (See 'Nutritional and metabolic abnormalities' below.)

The most commonly used bowel segments in urinary diversions include the distal ileum and/or cecum and the ascending or sigmoid colon; these sites are associated with the fewest metabolic consequences.

The primary indications for the use of various bowel segments and the associated metabolic consequences and symptomatology are shown in the following table (table 2) [19,22-25]. In addition, the length and location of the segment used can affect the patient's postoperative bowel function.

Reconstructive techniques — Urinary diversion procedures following cystectomy fall into two general categories: incontinent diversions and continent reconstructions.

Incontinent urine diversion simply directs urine from the ureters through a segment of isolated bowel to the surface of the abdominal wall via a cutaneous stoma. There, urine drains continuously and is collected by an external appliance adhered to the skin surface [26]. The most common type of incontinent urinary diversion is an ileal conduit. (See 'Ileal conduits' below.)

By contrast, continent reservoirs collect and store urine internally and empty stored urine intermittently by catheterization via a cutaneous stoma or volitional voiding. The patient is thereby freed from the need for an external appliance.

A continent cutaneous diversion creates a low-pressure reservoir from a bowel segment and connects it to the skin via a continent channel. The patient empties the urine by self-catheterizing the continent channel. (See 'Continent cutaneous diversions' below.)

By contrast, an orthotopic neobladder connects the bowel segment to the intact urethra. This procedure allows the patient to void volitionally through the urethra, restoring a more natural voiding pattern. (See 'Orthotopic neobladders' below.)

The process of selecting a particular urinary diversion option is complex and will be presented after each procedure has been described in detail. Factors that should be considered include oncologic (cancer stage and location, urethral margin), surgical (available bowel segment, pelvic radiation, surgeon experience), and patient-related factors (comorbidity, lifestyle, quality of life expectations) (table 3). (See 'Procedural selection' below.)

ILEAL CONDUITS — Ileal conduits were the gold standard for urinary reconstruction before the advent of continent diversions [27]. Due to the relative ease of their formation and the shorter operative time, ileal conduits are often used in patients with significant medical comorbidities to minimize postoperative complications and the risk of reoperation. Ileal conduits remain the procedures of choice for many patients, especially those with a shorter life expectancy and those who cannot complete the necessary rehabilitation process to learn how to manage a continent diversion.

Techniques of ileal conduit — An ileal conduit serves as a method for urine to drain to the exterior. A segment of ileum is selected; the terminal 10 to 15 cm of ileum at the ileocecal junction is typically preserved to maintain adequate absorption of bile salts, vitamin B12, and fat-soluble vitamins. The isolated segment of ileum is exteriorized through the abdominal wall as a stoma, around which an appliance is secured to collect urine. The presence of the stoma and appliance can affect a patient's body image.

Patients with obesity may require a loop-type (Turnbull) stoma because a short bowel mesentery and thick abdominal wall may prevent the creation of an end-on stoma without undue tension [28].

Outcomes of ileal conduit — Ileal conduits have been used for decades since the first report in 1950 by Bricker [26], and therefore detailed information is available regarding the incidence of complications [27,29,30]. Despite the fact that ileal conduits are often performed for patients with significant medical comorbidities, the complication rates are comparable to those of continent diversions performed for generally healthier patients (table 4).

The outcomes of ileal conduits are best illustrated by a series of 412 patients followed for a median of 98 months; the frequency of complications ranged from 45 percent at five years to 94 percent at greater than 15 years [27]. The overall rate of complications associated with conduits is similar for ileum and colon segments among properly selected patients [27,31,32]. The most frequent complications are renal insufficiency, stomal problems, bowel problems, urinary tract infections, ureteral obstruction, and urinary calculi (in 27, 24, 24, 24, 14, and 9 percent, respectively) [27].

Parastomal hernias are another frequent complication after ileal conduit diversion. The incidence varies widely from 12 to 48 percent, depending on the definition used, the length of follow-up, and whether the diagnosis is made clinically or radiographically [30,33,34]. Factors that increase the risk for developing a parastomal hernia include female sex, obesity, low preoperative albumin, and prior abdominal surgery [34]. Approximately 40 percent of patients with clinically apparent parastomal hernias report symptoms, such as difficulties with the ostomy appliance (poor fit, leakage), pain, and incarceration. As subsequent surgical repair of a parastomal hernia has potential morbidity and high rates of hernia recurrence [35], prophylactic mesh placement at the time of ileal conduit creation is being evaluated in several randomized controlled trials and may prove to be a preferred approach to patients at increased risk for parastomal hernia development [35-38]. (See "Parastomal hernia" and "Prophylactic mesh for ventral incisional hernia prevention".)

CONTINENT CUTANEOUS DIVERSIONS — All continent cutaneous reservoirs rely upon a low-pressure pouch constructed of various detubularized bowel segments and a functional mechanism that connects the reservoir to the skin designed to prevent involuntary urine flow. The most obvious advantage of this type of diversion is the ability to avoid continuous urine drainage with the need for an external appliance. These continent cutaneous diversions require lifelong intermittent clean self-catheterization through the stoma both to empty the reservoir and to irrigate mucous.

Patient education, motivation, and manual dexterity are required to manage the stoma and perform the necessary self-catheterization successfully [29]. Although continent cutaneous diversions have been largely supplanted by the orthotopic neobladder, this procedure is used when avoidance of an external appliance is desired but the urethra or bladder neck is nonfunctional or involved by tumor.

Techniques of continent cutaneous diversions — Many technical variations exist based upon the type of valve mechanism constructed and the segment of intestine utilized. Examples include the Kock, Indiana, and Miami pouches [39-41]. The Kock pouch has fallen out of favor due to the technical complexity of constructing the continent nipple valve and a high rate of complications often requiring reoperation. The Indiana and Miami pouches rely on a tapered ileal segment and plicated ileocecal valve to maintain continence.

Using the in situ appendix as the continence mechanism and catheterizable limb has improved outcomes and lowered major complication rates [42], and it is a pouch design that can be performed in previously radiated patients [43,44].

Another modification uses a tubularized segment of terminal ileum as a ureteral substitute to allow a more proximal ureteroenteric anastomosis and avoid the use of distal ureteral segments that may have been within the fields of radiation. The length of the ileal limb can be tailored to achieve a tension-free anastomosis with the proximal left ureter in the retroperitoneum [45].

Outcomes of continent cutaneous diversions — The majority of studies have demonstrated the safety and functional benefits of continent cutaneous diversions, with daytime and nighttime continence rates reported in the range of 90 to 98 percent [46,47].

However, complication rates can be significant. As an example, among 112 patients receiving a modified Indiana pouch at a single institution, 90 percent experienced one or more complications at 41 months [48]. Incontinence (any leakage) was the most common complication (28 percent) [48]. The reported rates of incontinence vary significantly depending upon the criteria used to define incontinence and the length of follow-up [29,32,48-51].

Incontinence with a continent cutaneous diversion can be due to uninhibited pouch contractions, poor pouch compliance, or an incompetent continence mechanism. Pouch urodynamics are helpful in categorizing the cause of the incontinence.

In patients with a poorly compliant, high-pressure reservoir, an initial trial of anticholinergics is the preferred approach. Refractory cases usually benefit from augmenting the reservoir with a patch of bowel to decrease pressure and increase capacity.

Incompetent continence mechanisms usually require open revision, although minimally invasive approaches, such as injecting bulking agents, are often helpful for mild incontinence.

Other frequent and troublesome long-term complications involve the efferent limb and catheterizable stoma. The reported rate of stomal stenosis and difficulty in catheterizing the stoma is 4 to 15 percent [48,51]. Additional problems include stone formation within the pouch and urinary tract infections, which are observed in up to 20 percent of patients. Twenty-one percent required a reoperation, mostly for stomal stenosis [48].

ORTHOTOPIC NEOBLADDERS — Orthotopic neobladders are internal reservoirs connected to the native urethra that rely upon the external striated sphincter and a high-capacity, low-pressure reservoir for continence. Because this approach facilitates the restoration of normal self-image by approximating normal voiding, orthotopic neobladders have become the procedure of choice for many patients requiring reconstruction following cystectomy for bladder cancer [52].

Techniques of orthotopic neobladders — Neobladder reservoirs are constructed from a segment of detubularized intestine (usually ileum) and anastomosed to the native urethra.

Some neobladders (eg, the hemi-Kock) incorporate an antireflux mechanism to limit backflow of urine from the reservoir to the upper urinary tracts. Although this mechanism mimics the normal antireflux apparatus of the native bladder, its requirement is controversial, and most urologists do not perform this mechanism:

Proponents cite the detrimental upper tract changes seen in patients who are followed for 10 years or longer after ileal conduits or ureterosigmoidostomy, both of which are associated with free reflux of infected urine [53-56].

Opponents question the need for specific antireflux maneuvers for the following reasons:

Long-term complications of reflux with orthotopic neobladders have been predominantly seen in patients who have high-pressure reservoirs. Contemporary neobladder designs ensure low filling pressures.

Voiding pressures within orthotopic neobladders are generated via the Valsalva maneuver and exerted to all of the intra-abdominal contents, including the ureters and renal pelvis. This equal pressure distribution minimizes reflux during voiding. In addition, some neobladder designs (eg, the Studer reservoir) utilize a long isoperistaltic proximal limb, which provides resistance to retrograde flow, thereby providing additional antireflux protection [57,58]. Long-term follow-up of patients with neobladders that do not incorporate an antireflux design have confirmed that reflux-related complications are rare.

Ureteral anastomoses that are designed to prevent reflux may lead to a greater risk of complications (eg, ureteroenteric stricture, ischemic fibrosis of the antireflux valve, stone formation from staples used to construct the valve system), which contribute substantially to morbidities, including impaired renal function [59,60].

Orthotopic neobladders were initially limited to men. In women, urethra-sparing orthotopic substitution was thought to be associated with an increased risk of local recurrence and voiding dysfunction. With improved understanding of the female rhabdoid sphincteric (continence) mechanism, however, this approach has become technically feasible and oncologically safe in selected women as well [61]. The selection criteria for orthotopic neobladders are discussed below. (See 'General approach' below.)

Outcomes of orthotopic neobladders — The functional goals of an orthotopic neobladder are to maintain continence during both the day and night and to allow consistent emptying of the neobladder without the need for intermittent catheterization.

Continence after an orthotopic urinary diversion is dependent upon an intact external urinary sphincter and pelvic floor, adequate functional urethral length, a high-capacity/low-pressure reservoir, and the age of the patient. Attention to neobladder design, careful surgical technique, appropriate patient selection, and patient education all contribute to optimizing functional results [29,62].

Urinary continence — Generally speaking, continence continues to improve over the first year after surgery as the capacity and compliance of the neobladder increase [63,64]. The continence rate, however, can vary by day versus night, men versus women, and young versus old:

Daytime continence with orthotopic diversions is better and typically precedes nighttime urinary control by 6 to 12 months.

Daytime continence rates after orthotopic diversions generally exceed 85 to 90 percent at centers of excellence but have been reported to range from 47 to 100 percent depending on the definition of continence and the length of follow-up [56,65-69].

As with daytime control, nocturnal continence is achieved gradually over the first year once the capacity and compliance of the continent diversion increase. Satisfactory nighttime continence rates at one year range between 71 to 80 percent at high-volume centers [65,70,71]. However, many patients still require nighttime protection, as there is no communication between the contractions in the reservoir and the urinary sphincter, due to loss of afferent input from the detrusor to the central nervous system, and no corresponding increase in urethra resistance during filling. Nerve-sparing surgery, when appropriate, is associated with optimal diurnal continence.

In several large series comprised predominantly of men, daytime and nighttime continence rates ranged from 87 to 100 percent and 70 to 95 percent, respectively (table 5) [56]. In women, daytime continence rates were also very high (75 to 93 percent) at average follow-up durations of 20 to 33 months; nighttime rates were similar to those of men at 72 to 84 percent (table 6) [72-76].

Continence rates in individuals over age 70 are lower than those in younger patients.

Voiding dysfunction — A meta-analysis of more than 2000 patients showed a 4 to 25 percent rate of intermittent self-catheterization after neobladder diversion for incomplete emptying [62]. Reported causes of incomplete emptying include urethral angulation, elongation of the neobladder neck, the neobladder neck being in a nondependent portion of pouch, an oversized floppy neobladder, a preserved but dysfunctional native bladder neck, denervated proximal urethra, inadequate pelvic floor relaxation during voiding, and ineffective Valsalva straining [77].

Inadequate emptying of the neobladder in men is uncommon. In a single-institution series of 655 men, inadequate emptying (defined as a residual volume >100 mL) was observed in 75 cases (11.5 percent) [77]. In 52 patients, this was due to mechanical obstruction, most commonly either benign strictures of the neovesicourethral anastomosis or local tumor recurrence; in 38 of these cases bladder emptying was restored with a local urological procedure, while 14 required some form of long-term catheterization. In the 23 cases without a mechanical obstruction, failure of bladder emptying was dysfunctional, and intermittent or indwelling catheterization was required.

Women have a higher risk of requiring intermittent catheterization after orthotopic neobladders, ranging from 11 to 70 percent. The increased need for intermittent catheterization (due to urinary retention) in women is thought to be due in part to a posterior prolapse of the neobladder during Valsalva voiding. Urinary retention associated with female neobladders may be minimized if meticulous surgical technique is used to preserve the autonomous nerve fibers to the remnant urethra and omental flaps are used to provide additional support [78].

Quality of life — Comparisons between orthotopic diversion and incontinent cutaneous diversion are limited by inherent selection bias and the lack of validated instruments to measure bladder-cancer-specific health-related quality of life (QOL) [79]. For example, patients undergoing continent diversion report better baseline QOL levels for physical, urinary, and sexual function compared with patients receiving ileal conduit diversions [80].

Although some reports have noted improvements in various aspects of QOL (eg, body image) using newer reconstructive techniques such as orthotopic neobladder, few formal studies have documented an improvement in overall QOL [81-85]. A systematic overview of 15 published studies (only one prospective, none randomized) examining health-related QOL after radical cystectomy and urinary diversion for bladder cancer found insufficient data to conclude that any one form of urinary diversion was associated with a better QOL [86].

Ultimately, diversion type may not be the defining factor in QOL after cystectomy. Instead, other patient, social, or process factors may control long-term outcomes. While orthotopic diversion may provide several QOL benefits for selected patients, psychological adaptation to urinary diversion appears to result in similar QOL states for patients one year after surgery.

Critically, regardless of the selected urinary diversion type, there is excellent preservation of QOL following cystectomy across multiple domains [80]. Recovery of QOL occurs as early as three months after cystectomy, which provides further support for radical cystectomy as the standard for high-risk bladder cancer [80].

PROCEDURAL SELECTION — The primary goals in selecting a urinary diversion are to provide the patient with convenient, low-pressure urinary storage and the best quality of life with the lowest potential for short- and long-term complications.

General principles — Detailed evaluations of patients' medical, physical, and psychological status, as well as their social support systems, are required prior to selection of the appropriate urinary diversion procedure. The decision requires consideration of surgical, oncologic, medical, and psychosocial issues [87].

While patient preference is of the utmost importance, there are some absolute and relative contraindications to the use of various bowel segments and continent urinary reservoirs (table 7). In addition, patients should be informed that intraoperative findings may dictate a change in the planned form of urinary diversion; these include a foreshortened mesentery or cancer-related issues such as a positive urethral margin or gross extravesical disease precluding a negative surgical margin.

Even when an orthotopic neobladder is planned, patients should have a stoma site marked preoperatively by an enterostomal therapist if an ileal conduit is the alternative, in case it becomes necessary based upon intraoperative findings.

General approach — For most patients who require urinary diversion following cystectomy and are candidates for all three procedures, we suggest an orthotopic neobladder [52,63]. In appropriately selected patients, the creation of an orthotopic neobladder obviates the need for an external stoma and preserves body image without compromising cancer surgery. The patient needs to be fully educated about the necessary commitment to the rehabilitation process and needs to possess adequate manual dexterity to perform self-catheterization, if that becomes necessary.

The contraindications for orthotopic neobladder include [88]:

Insufficient bowel segment length.

Inability to perform self-catheterization. (See 'Psychosocial and medical considerations' below.)

Inadequate renal or hepatic function (eg, estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m2). (See 'Psychosocial and medical considerations' below.)

Cancer at the urethral margin. (See 'Urethral margin' below.)

Intractable urethral stricture.

A continent cutaneous diversion may still offer substantial advantages over an incontinent ileal conduit for patients who desire to avoid a stomal appliance but are not candidates for an orthotopic neobladder due to tumor involvement of the urinary outflow tract or who do not desire an orthotopic neobladder. Candidates for a continent cutaneous reservoir should be willing and able to self-catheterize and have sufficient bowel segment length and adequate renal and hepatic function as well.

From the patient's perspective, one of the primary reasons for choosing an orthotopic neobladder over continent cutaneous diversion is the maintenance of normal body image and function. Conversely, continent cutaneous diversion may offer a significantly better quality of life compared with an orthotopic neobladder with respect to social dryness.

An ileal conduit is used for the remaining patients who are candidates for neither option of continent diversion. There is no contraindication for an ileal conduit in patients who can tolerate a cystectomy.

Ileal conduit is the most commonly performed urinary diversion after radical cystectomy worldwide. It is associated with lower morbidity and reoperation rates compared with those of continent diversion options. It is also the procedure of choice for older adults as well as patients with anatomical constraints, poor hepatorenal function, and limited ability to self-catheterize [89].

Oncologic considerations — The primary goal of cystectomy for bladder cancer is control of the underlying tumor, and every effort must be made to avoid compromising the effectiveness of the resection. Disease extent and anatomic considerations can limit reconstructive options.

Urethral margin — Preservation of the urethra in patients with urothelial tumors in order to construct an orthotopic neobladder raises concerns about possible recurrence of cancer, since the transitional cell lining of the urethra may be particularly susceptible to the development of new tumors in these patients. (See 'Recurrent urothelial cancer' below.)

Creation of an orthotopic neobladder requires that the urethra be free of cancer. We recommend performing an intraoperative pathologic assessment of the distal urethral margin at the time of surgery (frozen section) before proceeding with an orthotopic neobladder, rather than relying upon preoperative criteria to predict urethral recurrence [88,90].

For men, intraoperative frozen section assessment of the urethral margin is required, even if the preoperative evaluation was negative. Transurethral prostatic biopsy was previously performed to assess prostatic urethral involvement prior to construction of an orthotopic neobladder [91]. However, biopsy results do not always correlate with final histology [92,93]. Furthermore, although microscopic involvement of the prostatic urethra may be predictive of a higher rate of urethral recurrence, lower-than-expected urethral recurrence rates have been observed in orthotopically reconstructed patients despite involvement of the prostate. Thus, routine preoperative prostatic biopsies are generally not required, although this can be the surgeon's preference [94].

In women, creation of an orthotopic neobladder is contraindicated when there is overt involvement of the urethra. Tumor involvement of the bladder neck or invasion of the anterior vaginal wall is associated with an increased risk of concomitant urethral involvement, often representing an absolute contraindication to an orthotopic diversion [95-99]. Such patients should be excluded from orthotopic diversion; however, select women with a negative full-thickness frozen section of their urethral margin can be safely reconstructed to the urethra [100].

Locally advanced disease — Locally advanced bladder cancer and/or regional node-positive disease used to be an absolute contraindication to a continent diversion. The concerns were having to treat a local recurrence and giving chemotherapy and radiation therapy to patients with a urinary reservoir.

The contemporary view is that orthotopic urethral diversions and continent cutaneous diversions can be used in selected patients with regional metastases or locally advanced disease as few such patients will experience complications that would disrupt neobladder function [65,101].

The dwell time of urine in the reservoirs during chemotherapy is a concern and can cause toxicity due to the risk of methotrexate absorption with methotrexate vinblastine doxorubicin cisplatin (MVAC) treatment [102]. This issue has generally been managed by the use of an indwelling catheter during the chemotherapy infusion along with increased hydration [103]. Placement of an indwelling catheter in reservoirs during aggressive hydration required for receiving cisplatin can also avoid the risk of specific issues related to the reservoir, such as overdistension or rupture.

Data are limited regarding the proportion of patients in whom adjuvant chemotherapy is delayed by postoperative complications. However, neoadjuvant, rather than adjuvant, chemotherapy is generally used in patients with muscle-invasive bladder cancer because of a survival benefit [104]. (See "Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder" and "Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer".)

Minimally invasive urinary diversion — Minimally invasive approaches for radical cystectomy are increasingly being adopted at some centers [105-107]. While all minimally invasive radical cystectomies are performed laparoscopically or robotically, the urinary diversion portion of the procedure can be performed either extracorporeally or intracorporeally due to time and technical constraints.

Extracorporeal diversion – To date, most randomized trials comparing open with robotic cystectomies have used extracorporeal diversions through a mini-laparotomy and have shown similar short-term complication rates and oncologic outcomes [108-110]. When constructing an extracorporeal urinary diversion, it is important to maintain a robust blood supply to the ureters to minimize the risk of ureteroenteric strictures [111,112].

Intracorporeal diversion – As more surgeons become comfortable with robotic cystectomy, there is increasing interest in performing intracorporeal urinary diversions [113]. The iROC trial reported that a robotic-assisted radical cystectomy with a completely intracorporeal urinary diversion had some short-term benefits over open cystectomy, including 2.2 (95% CI 0.50-3.85) fewer days in the hospital in the first 90 days, less blood loss, fewer wound complications and venous thrombotic events, and better quality of life scores at up to 12 weeks [114].

With the growing popularity of minimally invasive radical cystectomy, there is also concern that patients who would otherwise be excellent candidates for (open) continent urinary diversions have instead been treated with intracorporeal incontinent diversions [115]. A completely intracorporal approach to both neobladder urinary diversions [116] and cutaneous catheterizable pouches [117] are feasible but present a technically challenging operation.

A single-center randomized controlled trial of open versus robotic radical cystectomy with extracorporeal diversion reported use of orthotopic neobladder urinary diversion in 55 percent of patients in each arm of the trial [118]. By contrast, in the iROC trial, only 12 percent (19 of 161) in the robotic intracorporeal urinary diversion and only 10 percent (16 of 156) in the open group underwent a continent/neobladder diversion [114].

While the National Cancer Database demonstrated increasing utilization of minimally invasive approaches for radical cystectomy, the American College of Surgeons National Surgical Quality Improvement Program has shown that utilization of orthotopic neobladder has decreased over time, with now fewer than 20 percent of patients receiving an orthotopic neobladder [119]. Similarly, European countries have also reported declining rates in the utilization of orthotopic neobladder from 33 percent in 2006 to 27 percent by 2014 [120].

While intracorporeal continent urinary diversions have been routinely performed by high-volume robotic bladder cancer surgeons, for less experienced surgeons, performing radical cystectomy robotically should not come at the expense of selecting an incontinent diversion for a patient who is a reasonable continent diversion. Thus, it is critical that surgeons performing robotic cystectomy continue to offer continent urinary diversions to appropriate candidates regardless of whether they perform the diversion through an intracorporeal or extracorporeal after a robotic cystectomy or opt for an open cystectomy with urinary diversion.

Diversion after pelvic radiation therapy — Precystectomy pelvic radiation therapy (RT) was formerly thought to impair functional outcomes (particularly continence) and increase postoperative complications (eg, wound infections, ureteroileal anastomotic leaks) from urinary diversions. These concerns arose from earlier reports of a high incidence of serious complications following salvage cystectomy after failure of primary RT for bladder cancer [121,122].

However, more contemporary studies support the feasibility of continent urinary diversions in irradiated patients [123]:

In a retrospective series of 86 patients undergoing continent cutaneous diversion with Kock pouch, 44 of whom were previously irradiated, there were no significant differences between irradiated and nonirradiated patients with respect to operative time, intraoperative blood loss, or transfusion requirements [124]. The irradiated group had eight urine leaks (20 percent) with three requiring surgical repair, while the control group had five urine leaks (12 percent) with one requiring repair.

In a cohort of 18 patients who underwent cystectomy and orthotopic neobladder after pelvic RT, daytime and nighttime continence rates were only 67 and 56 percent, respectively [125]. However, for those with persistent postoperative incontinence, placement of an artificial urethral sphincter successfully restored complete voiding control in all patients with incontinence.

For patients who have had prior radiation therapy, careful attention should be paid to the character, viability, and vascularity of the tissues, particularly the ureters and urethra. The bowel segment to be used for diversion may need to be selected based upon intraoperative findings of irradiated bowel segments. Although the transverse colon has historically been used as a conduit in patients with prior pelvic radiation, there is still risk of ureteral-colonic stricture development [126]. Experience has shown that the ileum can be safely used in carefully selected patients [127]. Orthotopic neobladder reconstruction can also be performed with reasonable functional outcomes at experienced centers [125,128].

Radiation-induced blood vessel damage can result in ureteral stricture rates as high as 32 percent, prolonged incontinence in up to 44 percent of neobladder reconstructions, stomal stenosis in up to 39 percent of catheterizable channels, and fistulas in up to 7 percent [125,129,130]. Reoperation is required to address these complications in 8 to 69 percent of patients; the most common reasons for reoperation include stomal revisions, ureteral anastomotic revisions, and procedures to correct incontinence and repair of fistulas [125,129].

Psychosocial and medical considerations — The choice of urinary diversion has a significant impact on the long-term health-related quality of life for patients who undergo radical cystectomy, and each type of diversion is associated with its own unique set of advantages and disadvantages. Thus, clinicians must first determine if a patient is a candidate for each diversion option and counsel the patient on all feasible options. Only then should an option be selected based upon the patient's values and preferences. Multiple factors need to be considered when choosing the appropriate procedure for an individual patient:

The patient and caretaker should have realistic expectations about the outcome associated with each reconstruction option. They also need to understand the efforts that will be required on their part during the rehabilitation process. In addition, patients need to have sufficient manual dexterity to master self-catheterization if the decision is made to proceed with a continent diversion. In particular, women who desire a neobladder need to have manual dexterity given the risk of urinary retention. In addition to the clinician, the enterostomal nurse specialist can be invaluable in educating the patient and caretaker and assisting with the decision-making process [131].

Advanced age can complicate both the procedure and the rehabilitation process. However, physiologic age is more relevant, and no formal cutoff should be applied. Older patients need to be aware that recovery of continence may take longer than in younger patients. Nonetheless, the ultimate results seem to be similar to those achievable in younger patients [132,133]. Our policy is to offer orthotopic neobladder and continent cutaneous diversion to older patients if they are healthy and motivated enough to care for the diversion. If an older patient subsequently becomes unable to care for the continent diversion, then an indwelling Foley catheter may be placed into the diversion, similar to what might be done for the native bladder.

Obesity increases the technical difficulty of cystectomy and may complicate orthotopic neobladder construction [134]. However, the postoperative management of an ileal loop conduit or a continent reservoir is also more difficult in patients with obesity, and most surgeons do not consider obesity to be a contraindication to reconstruction with an orthotopic neobladder [135]. Many, including the authors, feel that reconstruction to the urethra may be the least complicated reconstructive option for patients with obesity. However, obesity may be associated with a higher incidence of a thickened, foreshortened mesenteric root, which can preclude the ability to anastomose an orthotopic urinary diversion to the native urethra.

Adequate renal function is required for the creation of any continent diversion. Urinary excretion products are resorbed through the mucosal surface, imposing an extra metabolic burden on the kidneys. Typically, only mild metabolic abnormalities will be observed in patients who have normal renal function. For those with more severe renal dysfunction with serum creatinine values >2.0 to 2.5 mg/dL (180 to 230 microM/L), or an eGFR rate of <45 mL/min/1.73 m2, an ileal conduit is preferred over other approaches. (See 'Impaired renal function' below.)

COMPLICATIONS — Reported early and long-term morbidity rates following urinary diversions range between 20 to 56 percent within the first 30 days after surgery, and from 28 to 94 percent beyond 30 days [27,49,136].

When using strict reporting criteria, as many as 64 percent of patients will experience a complication within 90 days of their radical cystectomy, including 67 percent during the operative hospital admission and 58 percent following discharge [137]. The most common complications are gastrointestinal complications (29 percent), followed by infectious complications (25 percent) and wound-related complications (15 percent) [137].

Diversion-related complications are specific to the type of diversion and are generally categorized into those involving the bowel anastomosis, those related to the type of reservoir/conduit, and those associated with the ureterointestinal anastomosis [29]. The complications seen with continent urinary diversions also differ by the time of occurrence (early versus long-term) (table 8) [29,32,48-51]. If one combines the reported percentage of early and late complications in large institutional series associated with each procedure, the risk of having a significant complication over the lifetime of the patient is approximately 8 to 10 percent for orthotopic neobladders and 18 to 38 percent for continent cutaneous reservoirs.

Complications unique to a particular type of diversion have been discussed in the appropriate sections above. Complications common to most or all types of diversions are further discussed below.

Infection — Infectious complications can contribute to acute morbidity and chronic renal insufficiency. Among the contributory factors are the following:

Intestinal segments that are used to fashion the reservoir/conduit are normally colonized with bacteria [138].

Incomplete voluntary voiding may leave residual urine, a nidus for infection.

Intermittent catheterization may introduce bacteria into the reservoir in a retrograde manner, especially if it is done carelessly.

After urinary diversion, patients do not require chronic suppressive antibiotic therapy unless there is a history of recurrent infections. Although the presence of small bowel intestinal mucosa appears to promote asymptomatic bacterial colonization, urosepsis rarely occurs unless the patient has recurrent urinary tract infections. This was illustrated in a series of 66 patients with orthotopic neobladders [139]. Asymptomatic bacteriuria was seen in 78 percent of the 55 patients who voided through an orthotopic neobladder, while only 39 percent developed urinary infection, and urosepsis rarely occurred, except in the context of recurrent urinary tract infections.

Impaired renal function — Progressive impairment of renal function over time is observed in some patients after urinary diversion. The development of urinary tract obstruction (at the site of either ureteral implantation or reservoir/conduit outflow), stones, and chronic infection are contributory factors. Careful surveillance for evidence of obstruction or stone formation and treatment of infection will allow for prompt intervention, which may prevent or minimize loss of renal function.

The most extensive data on clinically important impaired renal function come from a Surveillance, Epidemiology, and End Results (SEER) Medicare database study of a cohort of 4015 patients with normal renal function and no hydronephrosis who underwent radical cystectomy between 1992 and 2010, in which 84 percent were reconstructed with an ileal conduit and 16 percent with a continent diversion [140]. End-stage kidney disease developed in 7 percent of patients; the estimated risks of developing end-stage kidney disease at 5 and 10 years were 8 and 17 percent, respectively.

On multivariate analysis, the risk of developing end-stage kidney disease was not associated with whether patients had an ileal conduit or a continent diversion (hazard ratio 1.06, 95% CI 0.78-1.44). Neither was the choice of urinary diversion independently associated with decreased renal function (measured by estimated glomerular filtration rate) in other studies [141,142].

Absorption of urinary contents in a patient with renal insufficiency can result in chronic acidosis and in osteopenia/osteoporosis from mobilization of phosphate stores. Because ileal conduits have less contact time with urine compared with continent diversion options, they are preferred in patients with existing renal insufficiency. (See 'General approach' above.)

Nutritional and metabolic abnormalities — Exclusion of an ileal or colonic segment of bowel may result in malabsorption of bile salts and vitamin B12.

Extensive ileal resection can lead to lipid malabsorption and gallstone formation secondary to the loss of bile salts, which are absorbed in the terminal ileum. However, the ileal segments used for urinary reconstruction are generally short enough to avoid this problem [19]. In one study, 10 percent of men and 25 percent of women developed gallstones at a mean follow-up of 41 months after urinary diversion; these incidences were comparable to those seen in the American general population [143]. Excess loss of bile salts can also lead to chronic diarrhea. (See "Gallstones: Epidemiology, risk factors and prevention", section on 'Prolonged fasting/parenteral nutrition'.)

Vitamin B12 is primarily absorbed by the ileum. Thus, if an ileal segment is used for the urinary diversion, B12 deficiency can develop [19]. The true incidence of B12 deficiency that develops as a result of urinary diversion is unknown; long-term estimates range from 0 to as high as 33 percent five years after urinary reconstruction [56,65]. Periodic monitoring of B12 levels should be considered in all patients who undergo urinary diversion using the terminal ileum, particularly long-term survivors [144,145]. The authors recommend that B12 levels be monitored annually beginning three to five years following diversion and that patients be evaluated and treated for symptoms consistent with B12 deficiency. (See "Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Small intestinal inflammation or surgery'.)

The use of any bowel segment for a reservoir or conduit can cause metabolic abnormalities through the resorption of urinary metabolites via the intestinal mucosa [19].

Hyperchloremic metabolic acidosis can result from resorption of excreted metabolites through the intestinal mucosa of the diversion. Severe acidosis was a major problem following ureterosigmoidostomy but is less so with modern reconstructions using ileum and colon that have reduced contact between urine and bowel mucosa [19]. (See "Acid-base and electrolyte abnormalities with diarrhea".)

The long-term effects of uncorrected acidosis include osteomalacia from mineral dissolution and stimulation of osteoclasts. Chronic metabolic acidosis can occur in 5 to 13 percent of patients after urinary diversion, but it takes years of uncorrected acidosis before radiographic evidence of bone demineralization develops [146]. Population-based studies suggest that the risk of fractures increases as much as 21 percent following cystectomy and urinary diversion [147].

To reduce the likelihood of developing bone sequelae from chronic acidosis, patients with a venous bicarbonate level of less than 21 mmol/L should be considered for supplementation with oral sodium bicarbonate and potentially calcium and vitamin D [148-150]. Regardless of the type of diversion, regular monitoring of electrolytes and acid-base status should occur at both early and late follow-up visits to allow for the institution of appropriate corrective therapy as needed.

Intestinal cancer — Bowel segments used to construct urinary diversions are more susceptible to intestinal tumor development than bowel segments in the general population [151]. Chronic exposure to urine causes progressive changes, including relatively thin intestinal epithelium with villous atrophy that initially does not have dysplastic or neoplastic features [152].

The risk after an ureterosigmoidostomy (or variants) is higher than after other types of diversions due to the mixing of fecal and urinary stream [153,154]. The pathogenesis of such tumors remains uncertain but may involve a combination of carcinogenic action and mucosal cellular instability at the anastomotic site, leading first to dysplasia and subsequently to carcinoma. With a ureterosigmoidostomy, adenocarcinoma of the conduit develops after a median latency of 26 years [155]. Patients undergoing ureterosigmoidostomy should be given information concerning this risk and should undergo regular colonoscopic surveillance beginning five years after surgery [156,157].

Reservoir rupture — Spontaneous rupture of either a continent cutaneous reservoir or an orthotopic neobladder is rare [158]. Generally, this has been associated with poor compliance with catheterization of a continent cutaneous reservoir or, rarely, with acute or chronic neobladder overdistention.

RECURRENT UROTHELIAL CANCER — The incidence of urethral recurrence after radical cystectomy ranges from 0.5 to 18 percent [95,159-168]; a meta-analysis including more than 3100 patients described an overall risk of 8 percent [96,167].

Risk factors — Risk factors associated with urethral recurrence after radical cystectomy include multifocal disease, carcinoma in situ (CIS), upper tract urothelial carcinoma, and involvement of the bladder neck or prostatic urethra [95,159-171].

In men, one of the most important risk factors for urethral recurrence is prostatic stromal invasion [90,92,172,173]. In a study of 436 radical cystectomy patients, the five-year probability of urethral recurrence was 6 percent for patients without prostatic involvement, compared with 15 percent for patients with superficial involvement and 21 percent for those with stromal invasion of the prostate [95].

In a study of 235 consecutive patients undergoing radical cystoprostatectomy, 33 percent of specimens had prostatic urothelial carcinoma, of which 64 percent had prostatic stromal invasion [174].

However, patients whose urinary stream has been diverted through the urethra have a lower-than-expected recurrence rate, despite the retention of the urethra. In some series, this has been observed even in men with tumor involvement of the prostatic urethra. In one series of 196 men undergoing cystoprostatectomy and orthotopic urinary diversion, only one had a urethral recurrence despite the finding of microscopic involvement of the prostatic urethra in 13 and foci of CIS in 83 [159].

Thus, although prostate tumor involvement is a risk factor for urethral recurrence, it should not preclude orthotopic diversion, provided that intraoperative frozen section analysis of the urethral margin after radical cystectomy is without evidence of tumor [88,90,160]. (See 'Urethral margin' above.)

Although data are more limited, oncologic outcomes in women appear to be similar to those in men [4,76,175]. As an example, in one series of 145 women with negative margins on frozen section at the time of cystectomy, only two (1.4 percent) developed isolated urethral recurrence [4].

When patients are properly selected for orthotopic diversion, the risk of urothelial recurrence is small, and close follow-up with prompt intervention for urethral recurrence can result in a good oncologic outcome [95,159-168].

Surveillance — Most recurrences are apparent within the first two years following cystectomy, although late recurrences have been reported [95,159-171]. Thus, regular follow-up of the retained urethra is indicated.

We follow patients with a urine cytology using either a voided or urethral wash specimen depending on the diversion, particularly patients at high risk (ie, those with CIS or any prostatic involvement at the time of cystectomy). We also urethroscope any patient with urethral-related symptoms, abnormal discharge, or hematuria.

However, the utility of surveillance programs (ie, urethral wash cytology) to monitor for urethral recurrence following cystectomy is controversial [176]:

Some studies have not demonstrated a difference in clinical outcome in screened patients compared with those followed clinically [177,178]. As an example, in a series of 176 men undergoing cystoprostatectomy with urinary diversion, urethral recurrence was documented in 13 of 48 monitored individuals (10 of whom underwent urethrectomy) and 16 of 128 patients who were followed clinically (all of whom underwent urethrectomy) [177]. There was no difference in the rate of disease progression regardless of the method of diagnosis.

On the other hand, proponents of surveillance argue that earlier diagnosis of an asymptomatic urethral recurrence provides a better chance for curative urethrectomy [168]. A poorer outcome in patients with more advanced urethral recurrences has been demonstrated, strongly supporting the use of techniques to detect recurrent disease at an early stage [161].

Management of recurrence — Urethral recurrence often presents with bloody urethral discharge, pelvic/perineal pain, and/or a mass in the urethra [95,159-168] and can occur up to 20 years after radical cystectomy [179].

The management of urethral recurrence after cystectomy is total urethrectomy, including excision of the meatus. Surgical management of these recurrences has limited morbidity, and, when revision of the diversion is indicated, a continent diversion can be maintained [95,159-168].

Transurethral management of noninvasive urethral recurrences has been described [95,162]. With proper patient selection, this approach may obviate a more invasive urethrectomy and revision of the urinary diversion. Intraurethral therapy with bacille Calmette-Guerin (BCG) has been described with mixed results [70,164]. (See "Treatment of primary non-muscle invasive urothelial bladder cancer".)

Patients with urethral recurrence and gross disease on cross-sectional imaging should be considered for systemic chemotherapy. (See "Treatment of metastatic urothelial carcinoma of the bladder and urinary tract".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Bladder cancer" and "Society guideline links: Cystectomy".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Beyond the Basics topic (see "Patient education: Bladder cancer treatment; muscle invasive cancer (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Types of urinary diversion after radical cystectomy – Urinary diversion is required following cystectomy for benign or malignant conditions. Ileal conduit, continent cutaneous diversion, and orthotopic neobladder are the three most commonly used techniques of urinary diversion. (See 'Introduction' above and 'Reconstructive options' above.)

Ileal conduit – Ileal conduits are the archetypical procedure of incontinent urinary diversions. Urine is directed from the ureters through a segment of isolated bowel to the surface of the abdominal wall via a cutaneous stoma. There, urine drains continuously and is collected by an external appliance adhered to the skin surface. (See 'Ileal conduits' above.)

Continent cutaneous diversion – Continent cutaneous diversions create a low-pressure reservoir from a bowel segment and connect it to the skin via a continent channel. The patient empties the urine by self-catheterizing the continent channel. (See 'Continent cutaneous diversions' above.)

Orthotopic neobladder – Orthotopic neobladders connect a bowel segment to the intact urethra. This procedure allows the patient to void volitionally through the urethra, restoring a relatively more natural voiding pattern. (See 'Orthotopic neobladders' above.)

How to select a method of diversion procedure – For most patients who require urinary diversion following cystectomy, we suggest an orthotopic neobladder (Grade 2C). An orthotopic neobladder obviates the need for an external stoma and preserves the patient's body image without compromising cancer surgery. The patient needs to have sufficient bowel segment length, adequate renal and hepatic reserve, no tumor involvement at the urethral margin or intractable urethral stricture, and the ability to self-catheterize if necessary. (See 'General approach' above.)

A continent cutaneous diversion may still offer substantial advantages over an incontinent ileal conduit for patients who desire to avoid a stomal appliance but are not candidates for an orthotopic neobladder due to tumor involvement of the urinary outflow tract or who do not desire an orthotopic neobladder. Patients seeking continent cutaneous diversions should be willing and able to self-catheterize and have sufficient bowel segment length and adequate renal and hepatic function.

An ileal conduit is used for the remaining patients who are candidates for neither option of continent diversion. There is no contraindication to an ileal conduit in patients who can tolerate a cystectomy.

Intraoperative pathologic assessment before orthotopic neobladder construction – Intraoperative pathologic assessment of the distal urethral margin is recommended at the time of surgery (frozen section) before proceeding with an orthotopic neobladder. Patients should be informed that intraoperative findings may dictate a change in the planned form of urinary diversion. (See 'Oncologic considerations' above and 'General principles' above.)

  1. Estape R, Mendez LE, Angioli R, Penalver M. Urinary diversion in gynecologic oncology. Surg Clin North Am 2001; 81:781.
  2. Petros JG, Augustinos P, Lopez MJ. Pelvic exenteration for carcinoma of the colon and rectum. Semin Surg Oncol 1999; 17:206.
  3. Kaefer M, Tobin MS, Hendren WH, et al. Continent urinary diversion: the Children's Hospital experience. J Urol 1997; 157:1394.
  4. Ali-el-Dein B, Abdel-Latif M, Ashamallah A, et al. Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study. J Urol 2004; 171:275.
  5. Adams MC, Mitchell ME, Rink RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol 1988; 140:1152.
  6. Kaveggia FF, Thompson JS, Schafer EC, et al. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990; 150:2389.
  7. McDougal WS, Koch MO. Accurate determination of renal function in patients with intestinal urinary diversions. J Urol 1986; 135:1175.
  8. Koch MO, McDougal WS, Flora MD. Urease and the acidosis of urinary intestinal diversion. J Urol 1991; 146:458.
  9. Koch MO, McDougal WS, Thompson CO. Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study with rats. J Urol 1991; 146:1390.
  10. Klein EA, Montie JE, Montague DK, et al. Jejunal conduit urinary diversion. J Urol 1986; 135:244.
  11. Plawker MW, Rabinowitz SS, Etwaru DJ, Glassberg KI. Hypergastrinemia, dysuria-hematuria and metabolic alkalosis: complications associated with gastrocystoplasty. J Urol 1995; 154:546.
  12. Nguyen DH, Bain MA, Salmonson KL, et al. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993; 150:707.
  13. Gosalbez R Jr, Woodard JR, Broecker BH, Warshaw B. Metabolic complications of the use of stomach for urinary reconstruction. J Urol 1993; 150:710.
  14. Filipsson S, Hultén L, Lindstedt G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978; 13:529.
  15. Thompson WG, Wrathell E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977; 20:461.
  16. Koch MO, McDougal WS. Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments. J Urol 1985; 134:165.
  17. Boyd SD, Schiff WM, Skinner DG, et al. Prospective study of metabolic abnormalities in patient with continent Kock pouch urinary diversion. Urology 1989; 33:85.
  18. Koch MO, Gurevitch E, Hill DE, McDougal WS. Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. J Urol 1990; 143:1275.
  19. Mills RD, Studer UE. Metabolic consequences of continent urinary diversion. J Urol 1999; 161:1057.
  20. Stampfer DS, McDougal WS, McGovern FJ. The use of in bowel urology. Metabolic and nutritional complications. Urol Clin North Am 1997; 24:715.
  21. McDougal WS, Stampfer DS, Kirley S, et al. Intestinal ammonium transport by ammonium and hydrogen exchange. J Am Coll Surg 1995; 181:241.
  22. Austin PF, DeLeary G, Homsy YL, et al. Long-term metabolic advantages of a gastrointestinal composite urinary reservoir. J Urol 1997; 158:1704.
  23. Lockhart JL, Davies R, Cox C, et al. The gastroileoileal pouch: an alternative continent urinary reservoir for patients with short bowel, acidosis and/or extensive pelvic radiation. J Urol 1993; 150:46.
  24. Ravi R, Dewan AK, Pandey KK. Transverse colon conduit urinary diversion in patients treated with very high dose pelvic irradiation. Br J Urol 1994; 73:51.
  25. Kato H, Igawa Y, Komiyama I, Nishizawa O. Continent urinary reservoir formation with transverse colon for patients with pelvic irradiation. Int J Urol 2002; 9:200.
  26. BRICKER EM. Bladder substitution after pelvic evisceration. Surg Clin North Am 1950; 30:1511.
  27. Madersbacher S, Schmidt J, Eberle JM, et al. Long-term outcome of ileal conduit diversion. J Urol 2003; 169:985.
  28. TURNBULL RB Jr. Intestinal stomas. Surg Clin North Am 1958; 38:1361.
  29. Farnham SB, Cookson MS. Surgical complications of urinary diversion. World J Urol 2004; 22:157.
  30. Kouba E, Sands M, Lentz A, et al. Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer. J Urol 2007; 178:950.
  31. Morales P, Golimbu M. Colonic urinary diversion: 10 years of experience. J Urol 1975; 113:302.
  32. Jahnson S, Pedersen J. Cystectomy and urinary diversion during twenty years--complications and metabolic implications. Eur Urol 1993; 24:343.
  33. Liu NW, Hackney JT, Gellhaus PT, et al. Incidence and risk factors of parastomal hernia in patients undergoing radical cystectomy and ileal conduit diversion. J Urol 2014; 191:1313.
  34. Donahue TF, Bochner BH, Sfakianos JP, et al. Risk factors for the development of parastomal hernia after radical cystectomy. J Urol 2014; 191:1708.
  35. Donahue TF, Bochner BH. Parastomal hernias after radical cystectomy and ileal conduit diversion. Investig Clin Urol 2016; 57:240.
  36. Liedberg F, Kollberg P, Allerbo M, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020; 78:757.
  37. Donahue TF, Cha EK, Bochner BH. Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. Curr Urol Rep 2016; 17:9.
  38. Movassaghi K, Shah SH, Cai J, et al. Incisional and Parastomal Hernia following Radical Cystectomy and Urinary Diversion: The University of Southern California Experience. J Urol 2016; 196:777.
  39. Bloch WE, Bejany DE, Penalver MA, Politano VA. Complications of the Miami pouch. J Urol 1992; 147:1017.
  40. Kock NG, Nilson AE, Nilsson LO, et al. Urinary diversion via a continent ileal reservoir: clinical results in 12 patients. J Urol 1982; 128:469.
  41. Rowland RG, Mitchell ME, Bihrle R, et al. Indiana continent urinary reservoir. J Urol 1987; 137:1136.
  42. Bochner BH, McCreath WA, Aubey JJ, et al. Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. Gynecol Oncol 2004; 94:140.
  43. Mirhashemi R, Lamrbou N, Hus N, et al. The gastrointestinal complications of the Miami Pouch: a review of 77 cases. Gynecol Oncol 2004; 92:220.
  44. Angioli R, Estape R, Cantuaria G, et al. Urinary complications of Miami pouch: trend of conservative management. Am J Obstet Gynecol 1998; 179:343.
  45. Bochner BH, Karanikolas N, Barakat RR, et al. Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. J Urol 2009; 182:2376.
  46. Sumfest JM, Burns MW, Mitchell ME. The Mitrofanoff principle in urinary reconstruction. J Urol 1993; 150:1875.
  47. Bihrle R. The Indiana pouch continent urinary reservoir. Urol Clin North Am 1997; 24:773.
  48. Holmes DG, Thrasher JB, Park GY, et al. Long-term complications related to the modified Indiana pouch. Urology 2002; 60:603.
  49. Killeen KP, Libertino JA. Management of bowel and urinary tract complications after urinary diversion. Urol Clin North Am 1988; 15:183.
  50. Parekh DJ, Gilbert WB, Koch MO, Smith JA Jr. Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. Urology 2000; 55:852.
  51. Webster C, Bukkapatnam R, Seigne JD, et al. Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol 2003; 169:174.
  52. Gschwend JE. Bladder substitution. Curr Opin Urol 2003; 13:477.
  53. Sullivan JW, Grabstald H, Whitmore WF Jr. Complications of ureteroileal conduit with radical cystectomy: review of 336 cases. J Urol 1980; 124:797.
  54. Middleton AW Jr, Hendren WH. Ileal conduits in children at the Massachusetts General Hospital from 1955 to 1970. J Urol 1976; 115:591.
  55. Richie JP, Skinner DG, Waisman J. The effect of reflux on the development of pyelonephritis in urinary diversion: an experimental study. J Surg Res 1974; 16:256.
  56. Steven K, Poulsen AL. The orthotopic Kock ileal neobladder: functional results, urodynamic features, complications and survival in 166 men. J Urol 2000; 164:288.
  57. Studer UE, Danuser H, Thalmann GN, et al. Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial. J Urol 1996; 156:1913.
  58. Boxer RJ, Fritzsche P, Skinner DG, et al. Replacement of the ureter by small intestine: clinical application and results of the ileal ureter in 89 patients. J Urol 1979; 121:728.
  59. Pantuck AJ, Han KR, Perrotti M, et al. Ureteroenteric anastomosis in continent urinary diversion: long-term results and complications of direct versus nonrefluxing techniques. J Urol 2000; 163:450.
  60. Shaaban AA, Abdel-Latif M, Mosbah A, et al. A randomized study comparing an antireflux system with a direct ureteric anastomosis in patients with orthotopic ileal neobladders. BJU Int 2006; 97:1057.
  61. Stenzl A, Höltl L. Orthotopic bladder reconstruction in women--what we have learned over the last decade. Crit Rev Oncol Hematol 2003; 47:147.
  62. Steers WD. Voiding dysfunction in the orthotopic neobladder. World J Urol 2000; 18:330.
  63. Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol 2003; 169:834.
  64. Varol C, Studer UE. Managing patients after an ileal orthotopic bladder substitution. BJU Int 2004; 93:266.
  65. Hautmann RE, de Petriconi R, Gottfried HW, et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999; 161:422.
  66. Studer UE, Danuser H, Hochreiter W, et al. Summary of 10 years' experience with an ileal low-pressure bladder substitute combined with an afferent tubular isoperistaltic segment. World J Urol 1996; 14:29.
  67. Lee KS, Montie JE, Dunn RL, Lee CT. Hautmann and Studer orthotopic neobladders: a contemporary experience. J Urol 2003; 169:2188.
  68. Stein JP, Lieskovsky G, Ginsberg DA, et al. The T pouch: an orthotopic ileal neobladder incorporating a serosal lined ileal antireflux technique. J Urol 1998; 159:1836.
  69. Bedük Y, Türkölmez K, Baltaci S, Göğüş C. Comparison of clinical and urodynamic outcome in orthotopic ileocaecal and ileal neobladder. Eur Urol 2003; 43:258.
  70. Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol 2006; 176:161.
  71. Stein JP, Dunn MD, Quek ML, et al. The orthotopic T pouch ileal neobladder: experience with 209 patients. J Urol 2004; 172:584.
  72. Ali-el-Dein B, el-Sobky E, Hohenfellner M, Ghoneim MA. Orthotopic bladder substitution in women: functional evaluation. J Urol 1999; 161:1875.
  73. Stenzl A, Jarolim L, Coloby P, et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer 2001; 92:1864.
  74. Hautmann RE, de Petriconi R, Kleinschmidt K, et al. Orthotopic ileal neobladder in females: impact of the urethral resection line on functional results. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:224.
  75. Arai Y, Okubo K, Konami T, et al. Voiding function of orthotopic ileal neobladder in women. Urology 1999; 54:44.
  76. Stein JP, Penson DF, Lee C, et al. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol 2009; 181:2052.
  77. Simon J, Bartsch G Jr, Küfer R, et al. Neobladder emptying failure in males: incidence, etiology and therapeutic options. J Urol 2006; 176:1468.
  78. Stenzl A, Colleselli K, Poisel S, et al. The use of neobladders in women undergoing cystectomy for transitional-cell cancer. World J Urol 1996; 14:15.
  79. Imbimbo C, Mirone V, Siracusano S, et al. Quality of Life Assessment With Orthotopic Ileal Neobladder Reconstruction After Radical Cystectomy: Results From a Prospective Italian Multicenter Observational Study. Urology 2015; 86:974.
  80. Clements MB, Atkinson TM, Dalbagni GM, et al. Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. Eur Urol 2022; 81:294.
  81. Dutta SC, Chang SC, Coffey CS, et al. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol 2002; 168:164.
  82. Hobisch A, Tosun K, Kinzl J, et al. Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol 2000; 18:338.
  83. Smith JA. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? J Urol 2003; 170:331.
  84. Månsson A, Davidsson T, Hunt S, Månsson W. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? BJU Int 2002; 90:386.
  85. Henningsohn L, Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002; 168:168.
  86. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005; 173:1318.
  87. Link RE, Lerner SP. Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol 2001; 19:24.
  88. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 2017; 198: 552. Available at: http://www.auanet.org/guidelines/muscle-invasive-bladder-cancer-new-(2017) (Accessed on September 27, 2017).
  89. Siddiqui KM, Izawa JI. Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy. World J Urol 2016; 34:19.
  90. Lebret T, Hervé JM, Barré P, et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol 1998; 33:170.
  91. Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol 1990; 144:666.
  92. Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol 2001; 165:1580.
  93. Kassouf W, Spiess PE, Brown GA, et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol 2008; 180:164.
  94. von Rundstedt FC, Mata DA, Shen S, et al. Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy. J Clin Urol 2016; 9:404.
  95. Freeman JA, Tarter TA, Esrig D, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996; 156:1615.
  96. Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002; 41:124.
  97. Stein JP, Esrig D, Freeman JA, et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 1998; 51:951.
  98. Stenzl A, Colleselli K, Poisel S, et al. Anterior exenteration with subsequent ureteroileal urethrostomy in females. Anatomy, risk of urethral recurrence, surgical technique, and results. Eur Urol 1998; 33 Suppl 4:18.
  99. Maralani S, Wood DP Jr, Grignon D, et al. Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. Urology 1997; 50:537.
  100. Miura H, Hatakeyama S, Tanaka T, et al. Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction. Urol Oncol 2023; 41:254.e17.
  101. Hautmann RE, Simon J. Ileal neobladder and local recurrence of bladder cancer: patterns of failure and impact on function in men. J Urol 1999; 162:1963.
  102. Srinivas S, Mahalati K, Freiha FS. Methotrexate tolerance in patients with ileal conduits and continent diversions. Cancer 1998; 82:1134.
  103. Bulbul MA, Wazzan W, Farhat W, et al. Feasibility of radiation and chemotherapy following cystectomy and orthotopic neobladder for invasive bladder cancer. Can J Urol 1998; 5:469.
  104. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005.
  105. Leow JJ, Reese SW, Jiang W, et al. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol 2014; 66:569.
  106. Hanna N, Leow JJ, Sun M, et al. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol 2018; 36:88.e1.
  107. Zamboni S, Soria F, Mathieu R, et al. Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. BJU Int 2019; 124:656.
  108. Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018; 391:2525.
  109. Bochner BH, Sjoberg DD, Laudone VP, Memorial Sloan Kettering Cancer Center Bladder Cancer Surgical Trials Group. A randomized trial of robot-assisted laparoscopic radical cystectomy. N Engl J Med 2014; 371:389.
  110. Khan MS, Gan C, Ahmed K, et al. A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol 2016; 69:613.
  111. Anderson CB, Morgan TM, Kappa S, et al. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol 2013; 189:541.
  112. Goh AC, Belarmino A, Patel NA, et al. A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. Urology 2020; 135:57.
  113. Smith AB, Raynor M, Amling CL, et al. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech A 2012; 22:17.
  114. Catto JWF, Khetrapal P, Ricciardi F, et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA 2022; 327:2092.
  115. Hussein AA, May PR, Jing Z, et al. Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol 2018; 199:1302.
  116. Goh AC, Gill IS, Lee DJ, et al. Robotic intracorporeal orthotopic ileal neobladder: replicating open surgical principles. Eur Urol 2012; 62:891.
  117. Goh AC, Aghazadeh MA, Krasnow RE, et al. Robotic Intracorporeal Continent Cutaneous Urinary Diversion: Primary Description. J Endourol 2015; 29:1217.
  118. Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol 2015; 67:1042.
  119. Bachour K, Faiena I, Salmasi A, et al. Trends in urinary diversion after radical cystectomy for urothelial carcinoma. World J Urol 2018; 36:409.
  120. Groeben C, Koch R, Baunacke M, et al. Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014. Ann Surg Oncol 2018; 25:3502.
  121. Smith JA Jr, Whitmore WF Jr. Salvage cystectomy for bladder cancer after failure of definitive irradiation. J Urol 1981; 125:643.
  122. Swanson DA, von Eschenbach AC, Bracken RB, Johnson DE. Salvage cystectomy for bladder carcinoma. Cancer 1981; 47:2275.
  123. Salom EM, Mendez LE, Schey D, et al. Continent ileocolonic urinary reservoir (Miami pouch): the University of Miami experience over 15 years. Am J Obstet Gynecol 2004; 190:994.
  124. Ahlering TE, Kanellos A, Boyd SD, et al. A comparative study of perioperative complications with Kock pouch urinary diversion in highly irradiated versus nonirradiated patients. J Urol 1988; 139:1202.
  125. Bochner BH, Figueroa AJ, Skinner EC, et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 1998; 160:29.
  126. Segreti EM, Morris M, Levenback C, et al. Transverse colon urinary diversion in gynecologic oncology. Gynecol Oncol 1996; 63:66.
  127. Chang SS, Alberts GL, Smith JA Jr, Cookson MS. Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol 2004; 22:272.
  128. Hautmann RE, de Petriconi R, Volkmer BG. Neobladder formation after pelvic irradiation. World J Urol 2009; 27:57.
  129. Gheiler EL, Wood DP Jr, Montie JE, Pontes JE. Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy. Urology 1997; 50:580.
  130. Wammack R, Wricke C, Hohenfellner R. Long-term results of ileocecal continent urinary diversion in patients treated with and without previous pelvic irradiation. J Urol 2002; 167:2058.
  131. van Savage JG, Slaughenhoupt BL. Approach to urinary diversion in the surgical patient. J Surg Oncol 2000; 73:33.
  132. Sogni F, Brausi M, Frea B, et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008; 71:919.
  133. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer 2005; 104:36.
  134. Lee CT, Dunn RL, Chen BT, et al. Impact of body mass index on radical cystectomy. J Urol 2004; 172:1281.
  135. Reyes MA, Nieder AM, Kava BR, et al. Does body mass index affect outcome after reconstruction of orthotopic neobladder? Urology 2007; 69:475.
  136. Perimenis P, Burkhard FC, Kessler TM, et al. Ileal orthotopic bladder substitute combined with an afferent tubular segment: long-term upper urinary tract changes and voiding pattern. Eur Urol 2004; 46:604.
  137. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164.
  138. Wullt B, Holst E, Steven K, et al. Microbial flora in ileal and colonic neobladders. Eur Urol 2004; 45:233.
  139. Wood DP Jr, Bianco FJ Jr, Pontes JE, et al. Incidence and significance of positive urine cultures in patients with an orthotopic neobladder. J Urol 2003; 169:2196.
  140. Zabell JR, Adejoro O, Konety BR, Weight CJ. Risk of end stage kidney disease after radical cystectomy according to urinary diversion type. J Urol 2015; 193:1283.
  141. Eisenberg MS, Thompson RH, Frank I, et al. Long-term renal function outcomes after radical cystectomy. J Urol 2014; 191:619.
  142. Gershman B, Eisenberg MS, Thompson RH, et al. Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. Int J Urol 2015; 22:651.
  143. Holmes DG, Park GY, Thrasher JB, et al. Incidence of cholelithiasis in 125 continent urinary diversions. J Urol 2001; 165:1897.
  144. Fujisawa M, Gotoh A, Nakamura I, et al. Long-term assessment of serum vitamin B(12) concentrations in patients with various types of orthotopic intestinal neobladder. Urology 2000; 56:236.
  145. Ganesan T, Khadra MH, Wallis J, Neal DE. Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. ANZ J Surg 2002; 72:479.
  146. Alcini E, D'Addessi A, Racioppi M, et al. Results of 4 years of experience with bladder replacement using an ileocecal segment with multiple transverse teniamyotomies. J Urol 1993; 149:735.
  147. Gupta A, Atoria CL, Ehdaie B, et al. Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. J Clin Oncol 2014; 32:3291.
  148. Hossain M. The osteomalacia syndrome after colocystoplasty; a cure with sodium bicarbonate alone. Br J Urol 1970; 42:243.
  149. Siklos P, Davie M, Jung RT, Chalmers TM. Osteomalacia in ureterosigmoidostomy: healing by correction of the acidosis. Br J Urol 1980; 52:61.
  150. Perry W, Allen LN, Stamp TC, Walker PG. Vitamin D resistance in osteomalacia after ureterosigmoidostomy. N Engl J Med 1977; 297:1110.
  151. North AC, Lakshmanan Y. Malignancy associated with the use of intestinal segments in the urinary tract. Urol Oncol 2007; 25:165.
  152. Aragona F, De Caro R, Parenti A, et al. Structural and ultrastructural changes in ileal neobladder mucosa: a 7-year follow-up. Br J Urol 1998; 81:55.
  153. Austen M, Kälble T. Secondary malignancies in different forms of urinary diversion using isolated gut. J Urol 2004; 172:831.
  154. Ali-El-Dein B, El-Tabey N, Abdel-Latif M, et al. Late uro-ileal cancer after incorporation of ileum into the urinary tract. J Urol 2002; 167:84.
  155. Pickard R. Tumour formation within intestinal segments transposed to the urinary tract. World J Urol 2004; 22:227.
  156. Azimuddin K, Khubchandani IT, Stasik JJ, et al. Neoplasia after ureterosigmoidostomy. Dis Colon Rectum 1999; 42:1632.
  157. Fichtner J. Follow-up after urinary diversion. Urol Int 1999; 63:40.
  158. Desgrandchamps F, Cariou G, Barthelemy Y, et al. Spontaneous rupture of orthotopic detubularized ileal bladder replacement: report of 5 cases. J Urol 1997; 158:798.
  159. Hassan JM, Cookson MS, Smith JA Jr, Chang SS. Urethral recurrence in patients following orthotopic urinary diversion. J Urol 2004; 172:1338.
  160. Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 2005; 173:1163.
  161. Clark PE, Stein JP, Groshen SG, et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 2004; 172:1342.
  162. Yossepowitch O, Dalbagni G, Golijanin D, et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003; 169:177.
  163. Huguet J, Palou J, Serrallach M, et al. Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol 2003; 43:495.
  164. Varol C, Thalmann GN, Burkhard FC, Studer UE. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol 2004; 172:937.
  165. Nieder AM, Sved PD, Gomez P, et al. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 2004; 64:950.
  166. Yoshida K, Nishiyama H, Kinoshita H, et al. Surgical treatment for urethral recurrence after ileal neobladder reconstruction in patients with bladder cancer. BJU Int 2006; 98:1008.
  167. Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol Clin North Am 1994; 21:645.
  168. Taylor JM, Spiess PE, Kassouf W, et al. Management of urethral recurrence after orthotopic urinary diversion. BJU Int 2010; 106:56.
  169. Levinson AK, Johnson DE, Wishnow KI. Indications for urethrectomy in an era of continent urinary diversion. J Urol 1990; 144:73.
  170. Tobisu K, Tanaka Y, Mizutani T, Kakizoe T. Transitional cell carcinoma of the urethra in men following cystectomy for bladder cancer: multivariate analysis for risk factors. J Urol 1991; 146:1551.
  171. Schellhammer PF, Whitmore WF Jr. Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 1976; 115:56.
  172. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001; 165:811.
  173. Donat SM, Genega EM, Herr HW, Reuter VE. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol 2001; 165:1117.
  174. Pettus JA, Carver BS, Masterson T, et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 2009; 73:328.
  175. Akkad T, Gozzi C, Deibl M, et al. Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center. J Urol 2006; 175:1268.
  176. Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003; 30:777.
  177. Knapik JA, Murphy WM. Urethral wash cytopathology for monitoring patients after cystoprostatectomy with urinary diversion. Cancer 2003; 99:352.
  178. Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 2003; 169:961.
  179. Van Poppel H, Sorgeloose T. Radical cystectomy with or without urethrectomy? Crit Rev Oncol Hematol 2003; 47:141.
Topic 2958 Version 32.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟